Morgan Stanley Maintains Bullish Stance on Sanofi Despite Target Adjustment

Morgan Stanley maintains Overweight rating on Sanofi ADRs, citing strong operations despite a technical price target cut to $55 due to currency pressures.

Analysts at Morgan Stanley have reaffirmed their positive outlook on Sanofi, maintaining an "Overweight" recommendation for the pharmaceutical giant's American Depositary Receipts (ADRs). This supportive stance persists even as the firm made a slight downward revision to its price target, moving from $56 to $55.

Currency Headwinds Prompt Technical Adjustment

The rationale for the updated target is attributed to foreign exchange pressures. Morgan Stanley's research indicates these headwinds are expected to impact the company's first-quarter 2026 results. The analysts project a negative currency effect of 1.8% on revenue and 2.5% on earnings per share (EPS) for that period. This assessment aligns closely with Sanofi's own guidance, which anticipates approximately 2% currency drag on full-year sales and around 3% on EPS. The bank characterizes this change as a technical correction rather than a fundamental reassessment of the company's value.

Underlying Operational Momentum Viewed Favorably

The core message from the analysis remains decidedly optimistic. Morgan Stanley evaluates Sanofi's operational performance as stronger than general market expectations. The company's management forecast—which calls for high single-digit sales growth at constant exchange rates—is viewed as a conservative estimate. The bank identifies potential for upward revisions to guidance as the year progresses, provided the current momentum in Sanofi's key business segments continues.

This perspective finds some resonance within the broader analyst community. The consensus average price target for Sanofi shares listed on Euronext Paris stands at €95.43. A note of caution comes from JPMorgan, which maintains a "Neutral" rating with a €95 target. Currently trading around €80.58, Sanofi's share price remains substantially below these consensus estimates. This valuation gap will face scrutiny on April 23, when the company is scheduled to release its official first-quarter financial results.